Frunevetmab Solensia in Cats

Frunevetmab, sold under the brand name Solensia, is a prescription monthly injection used to control pain associated with osteoarthritis in cats. It is a cat-specific monoclonal antibody rather than a traditional anti-inflammatory drug. In the United States, it is FDA-approved for cats and is given under the skin by your vet, usually every 28 to 30 days after your cat has been evaluated for arthritis pain and other possible causes of mobility changes.

This medication can be a helpful option for cats that have trouble with stairs, hesitate to jump, groom less, miss the litter box because climbing hurts, or seem quieter and less social than usual. Osteoarthritis is common in older cats, but it can also affect younger adults. Cornell notes that signs are often subtle, and Merck describes frunevetmab as a valuable treatment option for feline osteoarthritis pain. Solensia does not cure arthritis or rebuild damaged cartilage. Its role is pain control, which may improve movement, comfort, and quality of life when it matches the cat’s needs and overall health plan.

For many pet parents, one practical advantage is that Solensia avoids daily pilling. That matters because cats can be hard to medicate at home, and long-term oral pain control options are limited in this species. Still, response varies. Some cats improve after the first injection, while others need more than one monthly dose before the benefit is clear. Your vet may recommend tracking jumping, grooming, litter box use, and activity between visits so you can judge whether the medication is helping in a meaningful way.

Solensia works by targeting nerve growth factor, often shortened to NGF. NGF is involved in pain signaling and becomes important in osteoarthritic joints. Frunevetmab binds NGF and blocks it from activating pain pathways, which can reduce the pain signals traveling from sore joints to the nervous system. In plain language, it is designed to lower arthritis pain signaling rather than directly repairing the joint itself.

This mechanism is different from nonsteroidal anti-inflammatory drugs, or NSAIDs. NSAIDs affect inflammatory pathways through cyclooxygenase inhibition, while frunevetmab is a biologic therapy aimed at one pain-related target. Because it is a monoclonal antibody made for cats, it is not processed the same way as many oral drugs. That difference is one reason vets may consider it for cats that are difficult to medicate or for cats where long-term oral options are limited.

Clinical studies summarized in the prescribing information found better treatment success with Solensia than with vehicle control on owner-assessed and veterinarian-assessed arthritis outcome measures over repeated monthly dosing. Even so, not every cat responds the same way. The label also notes that anti-frunevetmab antibodies can develop and may potentially reduce effectiveness in some cats, so your vet may reassess the plan if improvement fades over time.

The most commonly reported adverse reactions in the field study included vomiting, injection-site pain, diarrhea, abnormal behavior or behavioral changes, renal insufficiency, decreased appetite, lethargy, dermatitis, hair loss, dehydration, lameness, itching, weight loss, scabbing on the head or neck, gingival disorders, bacterial skin infection, and otitis externa. In the Zoetis prescribing information, vomiting occurred in 13.2% of treated cats, injection-site pain in 10.9%, and diarrhea in 6.6%. Skin-related effects such as dermatitis, pruritus, alopecia, and scabbing are especially worth watching for at home.

Most side effects are mild to moderate, but any new vomiting, marked lethargy, facial swelling, hives, trouble breathing, collapse, severe itching, or sudden worsening after an injection should be treated as urgent. See your vet immediately if your cat has signs of an allergic reaction or seems significantly worse after treatment. Solensia should not be used in cats with known hypersensitivity to frunevetmab, and it should not be used in breeding, pregnant, or lactating cats.

The label also says the safe use of Solensia with concurrent NSAIDs has not been established in cats. In human anti-NGF programs, rapidly progressive osteoarthritis was reported when some patients received NSAIDs with anti-NGF therapy, although this syndrome has not been characterized or reported in cats. Because many senior cats also have kidney disease, gastrointestinal disease, or other chronic conditions, your vet may recommend baseline bloodwork and urinalysis and may monitor trends over time while deciding whether Solensia remains a good fit.

Solensia is given as a subcutaneous injection by your vet once a month. According to the U.S. prescribing information, cats are dosed by weight to target a minimum dose of 1 mg/kg, which is 0.45 mg/lb. Cats weighing 5.5 to 15.4 pounds, or 2.5 to 7 kg, receive 1 mL. Cats weighing 15.5 to 30.8 pounds, or 7.1 to 14 kg, receive 2 mL. The product is supplied as single-use 1 mL vials, and the full vial contents are administered based on the dosing chart.

This is not a medication pet parents give at home. Your vet administers it in the clinic, confirms that osteoarthritis is the likely pain source, and monitors response over time. If your cat is due for vaccines at the same visit, VCA notes that injections should be given at different sites on the body. If a monthly dose is missed, contact your vet to reschedule rather than doubling up or changing the interval on your own.

Improvement may appear within days to weeks, but some cats need more than one monthly injection before the benefit is obvious. Your vet may ask you to watch for practical changes such as easier jumping, better grooming, more social behavior, improved litter box use, or less stiffness after resting. If there is little benefit after an appropriate trial, your vet may discuss whether to continue, combine it with other supportive care, or switch to another arthritis management plan.

Published interaction data for Solensia are still limited compared with older medications. The U.S. label states that evaluations were not made to determine whether interactions occurred between Solensia and veterinary vaccines. VCA advises that if Solensia is given at the same time as a vaccination, it should be injected at a different site. That is a handling recommendation, not proof of a harmful interaction, but it shows why medication timing should be reviewed with your vet.

The more important caution involves concurrent NSAID use. The label says the safe use of Solensia with non-steroidal anti-inflammatory drugs has not been established in cats. That does not mean the combination is never considered, but it does mean your vet should weigh the potential benefits, the cat’s kidney and gastrointestinal status, and the limited feline safety data before combining therapies. This is especially relevant in older cats, where arthritis often overlaps with chronic kidney disease or other chronic illness.

Your vet should also know about every medication and supplement your cat receives, including gabapentin, joint supplements, omega-3 products, corticosteroids, and any recent injections or vaccines. Because Solensia is a biologic therapy, your vet may think about interactions differently than with standard oral drugs. The safest approach is a full medication review before each monthly injection, especially if your cat has developed new symptoms, skin changes, digestive upset, or reduced response over time.